Caspian Therapeutics shares preclinical data on KO-7246 for diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ACCV
3. SPY
4. QQQ
5. AZN
6. GMAB
7. IVBIY
8. IIB:IN
9. SPCX
10. APO

Go back to Caspian Therapeutics shares preclinical data on KO-7246 for diabetes

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

September 29, 2026 5:15 AM EDT


KO-7246 regenerated functional -cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models

KO-7246 has potential to complement existing diabetes therapies with a novel mechanism of action, evidenced by post-treatment durability and combination benefit with semaglutide

Findings highlight a potentially disease-modifying approach designed to restore the bodys own endogenous insulin-producing capacity

Caspian is building a leadership position in menin-directed therapies for diabetes and other cardiometabolic diseases

Management to host webcast and... More